Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML

Many older patients (pts) with relapsed or refractory (R/R) AML cannot tolerate intensive conditioning treatment and are not eligible for a potentially curative allogeneic hematopoietic cell transplant (alloHCT). 131I-apamistamab, an anti-CD45 radioimmunoconjugate, safely delivers high-dose targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells. Thus, 131I-apamistamab led induction and conditioning can provide these pts access to alloHCT. Here, we analyzed whether a dose-response relationship could be established between radiation dose to liver or bone marrow and rate of primary endpoint dCR.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: George L Chen, Camille Abboud, Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil H. Abhyankar, James Foran, Sameem Abedin, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sa Tags: 140 Source Type: research